MXCT
NASDAQMaxCyte Inc.
Price$1.22+0.01 (+0.83%)
01:30 PM02:45 PM
News · 26 weeks34+233%
2025-12-282026-06-21
Mix2590d
- Insider12(48%)
- SEC Filings9(36%)
- Other2(8%)
- Earnings2(8%)
Latest news
25 items- INSIDERDirector Johnston John Joseph was granted 30,421 shares, increasing direct ownership by 18% to 201,581 units (SEC Form 4)4 - MAXCYTE, INC. (0001287098) (Issuer)
- INSIDERDirector Hemrajani Rekha was granted 30,421 shares, increasing direct ownership by 76% to 70,314 units (SEC Form 4)4 - MAXCYTE, INC. (0001287098) (Issuer)
- INSIDERDirector Erck Stanley C was granted 30,421 shares, increasing direct ownership by 8% to 428,749 units (SEC Form 4)4 - MAXCYTE, INC. (0001287098) (Issuer)
- INSIDERDirector Douglas Richard was granted 30,421 shares, increasing direct ownership by 13% to 260,998 units (SEC Form 4)4 - MAXCYTE, INC. (0001287098) (Issuer)
- INSIDERDirector Collins Cynthia was granted 30,421 shares, increasing direct ownership by 38% to 111,310 units (SEC Form 4)4 - MAXCYTE, INC. (0001287098) (Issuer)
- INSIDERDirector Brooke William W was granted 30,421 shares, increasing direct ownership by 20% to 181,300 units (SEC Form 4)4 - MAXCYTE, INC. (0001287098) (Issuer)
- INSIDERDirector Balthrop Patrick J was granted 30,421 shares, increasing direct ownership by 60% to 80,998 units (SEC Form 4)4 - MAXCYTE, INC. (0001287098) (Issuer)
- INSIDERDirector Al-Wakeel Yasir B. was granted 30,421 shares, increasing direct ownership by 60% to 80,998 units (SEC Form 4)4 - MAXCYTE, INC. (0001287098) (Issuer)
- SECMaxCyte Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - MAXCYTE, INC. (0001287098) (Filer)
- SECSEC Form 8-K filed by MaxCyte Inc.8-K - MAXCYTE, INC. (0001287098) (Filer)
- SECSEC Form 10-Q filed by MaxCyte Inc.10-Q - MAXCYTE, INC. (0001287098) (Filer)
- SECMaxCyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MAXCYTE, INC. (0001287098) (Filer)
- PRMaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 GuidanceFirst quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million MaxCyte's Board authorized a $10 million share repurchase program ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2026 financial results an
- SECSEC Form DEFA14A filed by MaxCyte Inc.DEFA14A - MAXCYTE, INC. (0001287098) (Filer)
- SECSEC Form DEF 14A filed by MaxCyte Inc.DEF 14A - MAXCYTE, INC. (0001287098) (Filer)
- PRMaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2026 after the U.S. market close on Tuesday, May 12th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and ar
- INSIDERSEC Form 4 filed by Ahuja Parmeet4 - MAXCYTE, INC. (0001287098) (Issuer)
- SECSEC Form S-8 filed by MaxCyte Inc.S-8 - MAXCYTE, INC. (0001287098) (Filer)
- INSIDERSEC Form 4 filed by Ahuja Parmeet4 - MAXCYTE, INC. (0001287098) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ahuja Parmeet3 - MAXCYTE, INC. (0001287098) (Issuer)
- INSIDERSEC Form 4 filed by Masoud Maher4 - MAXCYTE, INC. (0001287098) (Issuer)
- PRMaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 375,000 shares of MaxCyte's common stock and a service-based restricted stock unit ("RSU") award with respect to 187,500 shares of MaxCyte's common stock to Parmeet Ahuja in connection with his appointment as Chief Financial Officer of MaxCyte. The awards were granted unde
- SECMaxCyte Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - MAXCYTE, INC. (0001287098) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by MaxCyte Inc.SCHEDULE 13G/A - MAXCYTE, INC. (0001287098) (Subject)
- SECSEC Form 10-K filed by MaxCyte Inc.10-K - MAXCYTE, INC. (0001287098) (Filer)
MXCT FAQ
7 questionsWhat does MaxCyte Inc. do?
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and...Where does MXCT stock trade?
MaxCyte Inc. (MXCT) is listed on NASDAQ.What sector and industry is MXCT in?
MaxCyte Inc. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.When did MaxCyte Inc. go public?
MaxCyte Inc. (MXCT) completed its IPO in 2021.What are analysts saying about MXCT?
MaxCyte Inc. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Neutral on 2025-08-11.What companies are similar to MXCT?
Notable peers in the same industry include IQV (IQVIA Holdings Inc.), INCY (Incyte Corp.), PPD (PPD, Inc.), MEDP (Medpace Holdings Inc.), ICLR (ICON plc). Compare MXCT side-by-side with any of them on Quantisnow.How can I track MXCT on Quantisnow?
Quantisnow aggregates MaxCyte Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MXCT to receive live email and push alerts on every new disclosure.